Forza Wealth Management LLC Acquires 49 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Forza Wealth Management LLC increased its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 5.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 881 shares of the pharmaceutical company’s stock after acquiring an additional 49 shares during the period. Forza Wealth Management LLC’s holdings in Vertex Pharmaceuticals were worth $355,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Cooper Financial Group lifted its holdings in Vertex Pharmaceuticals by 16.1% in the fourth quarter. Cooper Financial Group now owns 4,682 shares of the pharmaceutical company’s stock valued at $1,885,000 after acquiring an additional 651 shares during the period. Wedmont Private Capital grew its position in Vertex Pharmaceuticals by 11.8% during the fourth quarter. Wedmont Private Capital now owns 3,633 shares of the pharmaceutical company’s stock valued at $1,488,000 after buying an additional 384 shares during the period. Asset Allocation & Management Company LLC bought a new stake in Vertex Pharmaceuticals during the fourth quarter valued at approximately $228,000. Czech National Bank increased its holdings in Vertex Pharmaceuticals by 6.2% during the fourth quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock valued at $22,486,000 after buying an additional 3,260 shares during the last quarter. Finally, RMR Wealth Builders boosted its stake in shares of Vertex Pharmaceuticals by 9.0% during the 4th quarter. RMR Wealth Builders now owns 4,239 shares of the pharmaceutical company’s stock worth $1,707,000 after acquiring an additional 351 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Analysts Set New Price Targets

VRTX has been the topic of several analyst reports. HC Wainwright lowered their target price on Vertex Pharmaceuticals from $600.00 to $535.00 and set a “buy” rating on the stock in a research report on Friday, December 20th. Raymond James reiterated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Cantor Fitzgerald restated an “overweight” rating and set a $480.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, November 5th. Morgan Stanley increased their price objective on shares of Vertex Pharmaceuticals from $473.00 to $476.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. Finally, Wells Fargo & Company cut their price target on Vertex Pharmaceuticals from $555.00 to $460.00 and set an “overweight” rating for the company in a research note on Friday. Three equities research analysts have rated the stock with a sell rating, ten have issued a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $490.38.

Vertex Pharmaceuticals Trading Up 0.8 %

Shares of NASDAQ VRTX traded up $3.28 during midday trading on Monday, hitting $412.84. The company’s stock had a trading volume of 982,965 shares, compared to its average volume of 1,432,430. Vertex Pharmaceuticals Incorporated has a 12-month low of $377.85 and a 12-month high of $519.88. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The firm has a market cap of $106.32 billion, a P/E ratio of -207.46 and a beta of 0.40. The business’s 50 day moving average is $448.88 and its two-hundred day moving average is $467.95.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period last year, the company earned $3.67 earnings per share. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.